Immunotherapy

Hickey, M. J.; Malone, C. K.; Erickson, K. L.; Gerschenson, L. E.; Lin, A. H.; Inagaki, A.; Hiraoka, K.; Kasahara, N.; Mueller, B.; Kruse, C. A.; Kong, S.; Zhou, J.; Carter, B. S.; Junghans, R. P.; Sampath, P.; Lai, R. K.; Recht, L. D.; Reardon, D. A.; Paleologos, N.; Groves, M.; Rosenfeld, Myrna R.; Davis, T.; Green, J.; Heimberger, A.; Sampson, J.; Hashimoto, N.; Tsuboi, A.; Chiba, Y.; Kijima, N.; Oka, Y.; Kinoshita, M.; Kagawa, N.; Fujimoto, Y.; Sugiyama, H.; Yoshimine, T.; Birks, S. M.; Burnet, M.; Pilkington, G. J.; Yu, J. S.; Wheeler, C. J.; Nuno, M. A.; Richardson, J.E.; Fan, X.; Ji, J.; Chu, R. M.; Bender, J. G.; Hawkins, E. W.; Black, K. L.; Pollack, I. F.; Jakacki, R. I.; Butterfield, Lisa H.; Okada, H.; Hunt, M. A.; Pluhar, G. E.; Andersen, B. M.; Gallardo, J. L.; Seiler, C. O.; SantaCruz, Karen S.; Bauer, D. F.; Lamb, L. S.; Harmon, D. K.; X., Zheng,; Romeo, A. K.; Gillespie, G. Yancey; Parker, J. N.; Markert, J. M.; Jacobs, V. L.; Landry, R. P.; Leo, J. A. De; Bromberg, J. E.; Doorduijn, J.; Baars, J. W.; Imhoff, Gustaaf W. van; Enting, R.; Bent, Martin J. van den; Murphy, K. A.; Bedi, J.; Epstein, A.; Olin, M.; Andersen, B.; Swier, L.; Ohlfest, J.; Litterman, Adam J.; Zellmer, D. M.; Ohlfest, J. R.; Chiocca, E. A.; Aguilar, L. K.; Aguilar-Cordova, E.; Manzanera, Andrea G.; Harney, K. R.; Portnow, J.; Badie, B.; Lesniak, M.; Bell, S.; Ray-Chaudhuri, A.; Kaur, B.; Hardcastle, J.; Cavaliere, R.; McGregor, J.; Lo, S.; Chakarvarti, A.; Grecula, J.; Newton, H.; Trask, T. W.; Baskin, D. S.; New, P. Z.; Zeng, J.; See, A. P.; Phallen, J.; Belcaid, Z.; Durham, N.; Meyer, C.; Albesiano, E.; Pradilla, G.; Ford, E.; Hammers, H.; Tyler, B.; Brem, H.; Tran, P. T.; Pardoll, D.; Drake, C. G.; Lim, M.; Ghazi, A.; A., Ashoori,; Hanley, P.; Salsman, V.; Schaffer, D. R.; Grada, Z.; Kew, Y.; Z., Powell, S.; Grossman, R.; Scheurer, M. E.; Leen, A. M.; Rooney, C. M.; Bollard, C. M.; Heslop, H. E.; Gottschalk, S.; N., Ahmed,; Hu, J.; Patil, C.; Nuno, M.; Wheeler, C.; Rudnick, J.; Phuphanich, S.; Mazer, M.; Wang, H. Q.; Chu, R.; Black, K.; Yu, J.; Marabelle, A.; Kohrt, H.; Luong, R.; Tse, V.; Levy, R.; Thaipisuttikul, I.; Avila, E.; Friedman, H. S.; Herndon, J. E.; Bigner, D. D.; Johnson, L. A.; Archer, G. E.; Nair, S. K.; Schmittling, R.; Reap, E.; Sampson, J. H.; Mitchell, D. A.; Li, Y. M.; Shahryar, M.; Jun, H.; Daniel, V. A.; Walter, H. A.; Knisely, J. P.; Kluger, H.; Flanigan, J.; Sznol, M.; Yu, J. B.; Chiang, V. L.; Prins, R. M.; Kim, W.; Soto, H.; Lisiero, D. N.; Liau, L. M.

doi:10.1093/neuonc/nor151

Neuro-Oncology

2011

DOI: 10.1093/neuonc/nor151

|View full text |Cite

Immunotherapy

M. J. Hickey¹,

C. K. Malone²,

K. L. Erickson³

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2013

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Ipilimumab

2013

Reactions Weekly

View full text Add to dashboard Cite

S Ipilimumab Peripheral neuropathy: 2 case reportsTwo men developed severe peripheral neuropathy while receiving ipilimumab [routes not stated].A 57-year-old man received ipilimumab 10 mg/kg every 3 weeks after a melanoma resection. He developed rapidly progressive, painful sensory polyneuropathy after the second dose. He developed weakness of his distal lower extremities, and ipilimumab was discontinued. CSF studies showed elevated an protein level and WBC count. He received methylprednisolone, infliximab and immune globulin, but his condition deteriorated rapidly. He had no movement below the ankles, severe weakness, minimal strength in both hands and absent reflexes. His WBC and protein levels normalised within 5 days of receiving tacrolimus and methylprednisolone. At a 2-month follow-up, his symptoms had stabilised and his strength had improved.A 62-year-old man received ipilimumab 10 mg/kg for lung metastases, 7 years after resection of a melanoma. He developed dysaesthesias and experienced reduced proprioception below his ankles, after the fourth dose of ipilimumab. Ipilimumab was discontinued after the fifth dose, as he developed acute hepatitis. He received mycophenolate and methylprednisolone. His peripheral neuropathy resolved completely within a few months.

show abstract

Ipilimumab

2013

Reactions Weekly

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Immunotherapy

Cited by 1 publication

References 0 publications

Ipilimumab

Ipilimumab

Contact Info

Product

Resources

About